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Aims Heart failure is traditionally classified by left ventricular ejection fraction (LVEF), rather than by left ventricular (LV)
geometry, with guideline-recommended therapies in heart failure with reduced ejection fraction (HFrEF) but not
heart failure with preserved ejection fraction (HFpEF). Most patients with HFrEF have eccentric LV hypertrophy,
but some have concentric LV hypertrophy. We aimed to compare clinical characteristics, biomarker patterns, and
response to treatment of patients with HFrEF and eccentric vs. concentric LV hypertrophy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We performed a retrospective post-hoc analysis including 1015 patients with HFrEF (LVEF <40%) from the multi-
national observational BIOSTAT-CHF study. LV geometry was classified using two-dimensional echocardiography.
Network analysis of 92 biomarkers was used to investigate pathophysiologic pathways. Concentric LV hypertrophy
was present in 142 (14%) patients, who were on average older and more likely hypertensive compared to those with
eccentric LV hypertrophy. Network analysis revealed that N-terminal pro-B-type natriuretic peptide was an impor-
tant hub in eccentric hypertrophy, whereas in concentric hypertrophy, tumour necrosis factor receptor 1, urokinase
plasminogen activator surface receptor, paraoxonase and P-selectin were central hubs. Up-titration of beta-blockers
was associated with a mortality benefit in HFrEF with eccentric but not concentric LV hypertrophy (P-value for
interaction ≤0.001). For angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, the hazard ratio
for mortality was higher in concentric hypertrophy, but the interaction was not significant.
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Conclusion Patients with HFrEF with concentric hypertrophy have a clinical and biomarker phenotype that is distinctly different
from those with eccentric hypertrophy. Patients with concentric hypertrophy may not experience similar benefit from
up.-titration of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers compared
to patients with eccentric hypertrophy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Heart failure • Heart failure with reduced ejection fraction • Echocardiography • Left ventricular
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Introduction
Remodelling of the left ventricle is one of the most important
pathophysiological processes in heart failure. Four basic patterns
of left ventricular (LV) remodelling have been recognized: nor-
mal geometry, concentric remodelling, concentric hypertrophy and
eccentric hypertrophy. Current recommendations on LV chamber
quantification advise to classify LV geometry by using echocar-
diographically determined LV mass index (LVMI) and relative wall
thickness (RWT).1 Normal geometry is characterized by a normal
LMVI and RWT. In concentric remodelling, only RWT is increased.
In both concentric and eccentric hypertrophy, LVMI is increased,
with a normal RWT in eccentric hypertrophy and an increased
RWT in concentric hypertrophy. These four categories are illus-
trated in Figure 1. In this paper, we analysed differences between the
two types of hypertrophy. Eccentric hypertrophy, associated with
chronic volume overload, is characterized by increasing myocyte
length, which ultimately results in a dilated left ventricle with thin
walls.2 In contrast, in concentric hypertrophy, myocytes mainly
increase in short-axis diameter.3
Despite recognition of the importance of LV remodelling, heart
failure has traditionally been classified by LV ejection fraction
(LVEF) rather than LV geometry. Recently it has been argued
that more attention should be given to phenotyping heart failure
beyond ejection fraction alone.4 The most common type of LV
remodelling in heart failure with a reduced ejection fraction
(HFrEF) is eccentric hypertrophy. However, a subset of HFrEF
patients appear to have concentric hypertrophy.5 We aimed to
investigate the clinical characteristics between these two pat-
terns of LV hypertrophy in patients with HFrEF. In addition, we
performed a network analysis using circulating biomarkers to
gain insight into the underlying biological processes in the two
LV geometry groups. Finally, we assessed whether the type of
LV remodelling was associated with a differential response to
guideline-directed medical therapy in HFrEF.
Methods
Study population
We retrospectively analysed data from the BIOSTAT-CHF (A systems
BIOlogy Study to TAilored Treatment in Chronic Heart Failure) study.
BIOSTAT-CHF recruited patients with worsening heart failure from 11
European countries, between 2010 and 2015. Patients had to be antic-
ipated to be up-titrated with angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin receptor blockers (ARBs) and/or beta-blockers ..
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.. to be eligible.6 The study complies with the Declaration of Helsinki and
was approved by the medical ethics committees of all participating cen-
tres. All patients provided written informed consent. The index cohort
consisted of a total of 2516 patients with heart failure, of which a subset
of 1819 patients had an LVEF <40%. The echocardiographic variables
that define LV geometry (LVMI and RWT) were present in 1304 of
these patients (72%). Hypertrophy of either concentric or eccentric
type was present in 1015 patients. Patients with normal geometry
or concentric remodelling were not included in the present analy-
sis since they are less common, and we were specifically interested
in the pathophysiological differences between the two phenotypes of
hypertrophy. Baseline characteristics of patients with normal geometry
or concentric remodeling are provided in supplementary Table S3. A
flowchart of patient selection is provided in the online supplementary
Figure S6. We validated the results of the network analysis in an inde-
pendent validation cohort, consisting of 1738 patients from six centres
in Scotland. The validation cohort included 730 patients with a LVEF
<40%. Data on LV geometry were present in 328 of these patients
(45%). Baseline characteristics of the validation cohort are provided in
supplementary Table S1.
Echocardiography
Patients underwent two-dimensional echocardiography using a com-
mercially available echocardiograph with a 3.5MHz probe. There
was a median of two days between echocardiography and blood
sampling. The examination was performed according to current
guidelines and comprised: quantification of chamber and atrial
dimensions and LV mass. Chamber function was calculated using
LVEF according to the modified Simpson rule. Valvular function
was evaluated using two-dimensional and colour Doppler echocar-
diography. According to current guidelines, eccentric hypertrophy
was defined as LVMI >95 g/m2 for women and >115 g/m2 for
men with an RWT ≤0.42; concentric hypertrophy was defined
as LVMI >95 g/m2 for women and >115 g/m2 for men with
RWT >0.42.1
Laboratory analyses
A panel consisting of 92 cardiovascular disease-related biomarkers
(Olink CVD III panel) was measured in both the index and validation
cohorts. Measurements were performed by Olink Bioscience (Uppsala,
Sweden). The panel consists of known biomarkers of cardiovascular
disease and inflammation, as well as several promising new biomarkers,
selected to further elucidate cardiovascular pathophysiology. The panel
uses a proximity extension assay, in which 92 oligonucleotide-labelled
antibodies can bind to their targets.7 Real-time polymerase chain reac-
tion was performed thereafter, resulting in semi-quantitative normal-
ized protein expression levels.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Basic patterns of left ventricular remodelling.
Statistical analyses
Network analysis
Network analysis of protein–protein correlations was performed
using a method previously described.8 In brief, pairwise correlations
between were calculated in the subsets with concentric and eccen-
tric hypertrophy. P-values were corrected for multiple testing using
Benjamini–Hochberg procedure. Next, only significant correlations in
both index and validation cohorts were retained. Because the con-
centric and eccentric subgroups had a large difference in numbers, an
additional cut-off based on correlation strength (R2 >0.4) was used.
Network analysis with these lists of protein–protein interactions were
performed using Cytoscape version 3.6.1 (Cytoscape Consortium,
New York, NY, USA).9
Up-titration
BIOSTAT included heart failure patients aged ≥18 years, who were
using oral or intravenous diuretics at a dose of furosemide ≥40mg
or equivalent. At the time of inclusion, patients should not have
been previously treated with evidence-based therapies (ACEi/ARBs and
beta-blockers) or were receiving less than 50% of the target doses ..
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.. of these drugs. In addition, initiation or up-titration of ACEi/ARBs or
beta-blockers needed to be anticipated by the treating physician. For
this analysis, patients were considered to be successfully up-titrated
if they achieved at least 50% or more of the recommended treat-
ment dose for ACEi/ARBs or beta-blockers in the current Euro-
pean Society of Cardiology guidelines. To correct for treatment indi-
cation bias in all analyses estimating the effects of up-titration of
ACEi/ARBs and beta- blockers, we inversely weighted for the prob-
ability (IPW) of achieving the treatment.10 To determine IPW weights
we first imputed missing values five times using R package mice.
We then performed logistic regression on all five imputed datasets,
using LASSO penalization to obtain parsimonious logistic models from
an initial comprehensive list of 20 clinical and laboratory variables
and the 92 Olink biomarkers. To find the optimal lambda in our
LASSO regression, we performed 10 cross validations to increase
robustness. The IPW weights were calculated by the average proba-
bility of achieving recommended treatment dose, determined by the
LASSO regression models from all five imputed datasets for both
ACEi/ARBs and beta-blockers, separately. These IPW weights were
then used in our final Cox proportional hazards models comparing sur-
vival in concentric vs. eccentric hypertrophy for both ACEi/ARBs and
beta-blockers.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Scatterplot of 1015 patients with heart failure with
reduced ejection fraction classified as normal (red), concentric
remodelling (blue), concentric hypertrophy (green) and eccentric
hypertrophy (purple). RWT, relative wall thickness; LVMI, left
ventricular mass index.
Results
Baseline characteristics
Concentric hypertrophy was found in 142 of the 1015 patients
(14%) (Figure 2). Baseline characteristics of patients with concentric
vs. eccentric hypertrophy are shown in Table 1. Compared to
eccentric hypertrophy, HFrEF patients with concentric hypertro-
phy were on average older (70± 11 vs. 67± 12 years, P = 0.005)
and more likely to have a history of hypertension (77% vs. 58%,
P< 0.001). Likewise, hypertension was also the common primary
aetiology in concentric hypertrophy (20.4% vs. 8.3%, P< 0.001). In
contrast, a primary aetiology of cardiomyopathy was more preva-
lent in eccentric hypertrophy (32.4% vs. 20.4%, P = 0.003). Primary
aetiologies of ischaemic heart disease and valvular heart disease
were not different between groups. Smoking history was compa-
rable between concentric and eccentric hypertrophy as well. Renal
disease [defined as an estimated glomerular filtration rate (eGFR)
<60mL/min/1.73m2] was more prevalent (31% vs. 23%, P = 0.046)
and mean eGFR was lower in patients with concentric hyper-
trophy (57.7mL/min/1.73m2 vs. 61.9mL/min/1.73m2, P = 0.037).
The prevalence of atrial fibrillation was similar in concentric vs.
eccentric hypertrophy (45.1% vs. 40.4%, P = 0.298). Mean ejec-
tion fraction was higher in concentric hypertrophy (30.2± 6.2 vs.
26.5± 7.0, P< 0.001) although all patients had LVEF <40% by defi-
nition. The prevalence of moderate–severe mitral valve regurgita-
tion was lower in concentric hypertrophy (42% vs. 58% in eccen-
tric hypertrophy, P< 0.001). Overal survival stratified by geometry
group is given in supplementary Figure S1 (index cohort) and sup-
plementary Figure S2 (validation cohort). ..
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Table 1 Baseline characteristics
Concentric
hypertrohy
(n = 142)
Eccentric
hypertrophy
(n = 873)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 69.7 (11.4) 66.5 (11.8) 0.005
Female sex 43 (30.3%) 220 (25.2%) 0.200
BMI, kg/m2 28.4 (5.3) 27.5 (4.9) 0.059
SBP, mmHg 129.4 (21.1) 123.9 (21.3) <0.001
DBP, mmHg 78.3 (12.9) 75.7 (12.7) 0.028
NYHA class 0.683
I 12 (8.5%) 65 (7.4%)
II 62 (43.7%) 419 (48.0%)
III 51 (35.9%) 266 (30.5%)
IV 4 (2.8%) 25 (2.9%)
Not assessed 13 (9.2%) 98 (11.2%)
Heart rate, bpm 80.5 (18.0) 80.1 (17.7) 0.705
Medical history
Myocardial infarction 44 (31.0%) 332 (38.0%) 0.107
PCI 31 (21.8%) 176 (20.2%) 0.647
CABG 22 (15.5%) 138 (15.8%) 0.924
Valvular surgery 11 (7.7%) 55 (6.3%) 0.517
Moderate–severe
mitral regurgitation
59 (41.5%) 504 (57.9%) <0.001
Atrial fibrillation
(history)
64 (45.1%) 353 (40.4%) 0.298
Atrial fibrillation (ECG) 48 (33.8%) 258 (29.7%) 0.318
Hypertension 109 (76.8%) 526 (60.3%) <0.001
Diabetes 48 (33.8%) 259 (29.7%) 0.320
COPD 29 (20.4%) 148 (17.0%) 0.312
Renal disease 44 (31.0%) 203 (23.3%) 0.046
Current malignancy 5 (3.5%) 16 (1.8%) 0.190
Device therapy 0.025
Pacemaker 9 (6.3%) 56 (6.4%)
ICD 4 (2.8%) 90 (10.3%)
CRT-P 0 (0%) 17 (1.9%)
CRT-D 7 (4.9%) 47 (5.4%)
Smoking history 0.769
None 56 (39.4%) 318 (36.5%)
Past 63 (44.4%) 413 (47.4%)
Current 23 (16.2%) 141 (16.2%)
Primary aetiology
Ischaemic heart disease 65 (45.7%) 386 (44.2%) 0.833
Hypertension 29 (20.4%) 73 (8.3%) <0.001
Cardiomyopathy 29 (20.4%) 283 (32.4%) 0.003
Valvular heart disease 7 (4.9%) 50 (5.7%) 0.676
Other 12 (8.4%) 71 (8.1%) 0.799
Type of visit 0.108
Outpatient (scheduled) 35 (24.6%) 259 (29.7%)
Outpatient
(unscheduled)
6 (4.2%) 67 (7.7%)
Inpatient
hospitalization
101 (71.1%) 547 (62.7%)
NT-proBNP, ng/L 3862 2493 0.006
eGFR, mL/min/1.73m2 57.7 61.9 0.037
Urea, mmol/L 12.4 11.6 0.140
Haemoglobin, g/dL 13.4 (2.0) 13.4 (1.8) 0.762
ACEi/ARB use 99 (69.7%) 649 (74.3%) 0.246
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Continued
Concentric
hypertrohy
(n = 142)
Eccentric
hypertrophy
(n = 873)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Beta-blocker use 111 (78.2%) 742 (85.0%) 0.039
MRA use 71 (50.0%) 524 (60.0%) 0.025
Diuretic use 142 (100.0%) 872 (99.9%) 0.687
LVEF (%) 30.2 (6.2) 26.5 (7.0) <0.001
LVEDD (mm) 56.0 65.0 <0.001
LVMI (g/m2) 157.1 147.8 <0.001
RWT 0.47 0.31 <0.001
E/A ratio 1.0 (0.7, 2.0) 1.4 (0.7, 2.3) 0.717
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index; CABG, coronary artery bypass graft; COPD,
chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization ther-
apy with defibrillation; CRT-P, cardiac resynchronization therapy with pace-
maker; DBP, diastolic blood pressure; ECG, electrocardiogram; eGFR, estimated
glomerular filtration rate; ICD, implantable cardioverter-defibrillator; LVEDD,
left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction;
LVMI, left ventricular mass index; MRA, mineralocorticoid receptor antagonist;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention; RWT, relative wall thick-
ness; SBP, systolic blood pressure.
Network analysis
Patients with concentric hypertrophy showed 37 significant cor-
relations that could be successfully validated; of the total 37 cor-
relations, 15 were unique to concentric hypertrophy. Patients
with eccentric hypertrophy showed 28 significant correlations that
could be successfully validated; of the total 37 correlations, 8 were
unique to eccentric hypertrophy. Heatmaps of all protein–protein
correlations are provided in the online supplementary Figures S4
and S5. Protein–protein correlations that are unique to concentric
and eccentric hypertrophy, respectively, are presented in Figure 3.
For instance, the correlation between tumour necrosis factor
receptor 1 (TNF-R1) and interleukin-2 receptor alpha was only
present in the network analysis of concentric hypertrophy. The size
of the ’hub’ is related to the centrality of the hub in the network. In
other words, proteins that are implicated in a high number of other
protein–protein correlations are more important in the network,
and plotted as larger hubs. The most important hubs in eccen-
tric hypertrophy were N-terminal pro-B-type natriuretic peptide
(NT-proBNP) and junctional adhesion molecule A (JAM-A). In con-
centric hypertrophy, the main hubs were TNF-R1, urokinase plas-
minogen activator surface receptor (U-PAR), paraoxonase (PON3)
and P-selectin (SELP). The levels of the individual biomarkers used
for the network analysis are presented in the online supplementary
Table S2.
Effect of up-titration
Figure 4 shows model estimated probability of survival, com-
paring successfully up-titrated patients (having achieved ≥50% of
guideline-recommended dose) with patients who reached only
<50% of guideline-recommended dose for both beta-blockers ..
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.. and ACEi. Unweighted Kaplan-Meier curves are provided in sup-
plementary Figure S3. Up-titration of beta-blockers was signifi-
cantly associated with a survival benefit in patients with eccen-
tric hypertrophy [hazard ratio 0.48, 95% confidence interval (CI)
0.40–0.58, P≤ 0.001]. Such an effect could not be established
in patients with concentric hypertrophy (hazard ratio 0.87, 95%
CI 0.62–1.23, P = 0.41; P-value for interaction <0.001). For
ACEi/ARBs, successful up-titration resulted in a hazard ratio of 0.38
(95% CI 0.31–0.45, P< 0.001) for all-cause mortality in eccentric
hypertrophy compared to 0.63 (95% CI 0.43–0.94, P = 0.02) for
concentric hypertrophy. In contrast to beta-blockers, there was
no significant interaction between remodelling type and effects
of up-titration of ACEi/ARBs on outcome (P-value for interac-
tion = 0.68).
Discussion
From a large multinational longitudinal study we conclude that
patients with HFrEF vary in clinical characteristics and pathophys-
iology, and might respond different to medical therapy according
to LV geometry. The minority of patients with HFrEF had con-
centric LV hypertrophy. The classic depiction of the natural his-
tory of HFrEF begins with an initial index event that damages the
myocardium, followed by activation of compensatory mechanisms
that include LV hypertrophy, and attempts to stabilize contractility
and cardiac output through neurohormonal activation, which lead
to further LV systolic dysfunction. Progressive LV dilatation, wall
thinning and eccentric remodelling, occurring along with a decline
in LVEF, has been proposed as a therapeutic target in and of itself in
the biomechanical model of heart failure.11 It is therefore surpris-
ing that a sizeable proportion of our patients with HFrEF showed
a clear reduction in LVEF without eccentric remodelling, and had
concentric remodelling instead. Patients with concentric hypertro-
phy had similarly advanced New York Heart Association functional
class and even higher NT-proBNP and worse renal function, com-
pared to those with eccentric hypertrophy — thus arguing against
concentric hypertrophy being an earlier or milder form of HFrEF.
Instead, patients with HFrEF and concentric hypertrophy were
more predominantly older hypertensive women — a profile usu-
ally indicative for HFpEF. Of interest, the prevalence of moderate
or severe mitral regurgitation was higher in patients with eccentric
hypertrophy, even though valvular heart disease as aetiology was
not different between groups. These findings might be explained by
secondary mitral annular dilatation, which is often seen in dilated,
eccentric remodelled hearts leading, to malcoaptation of mitral
leaflets.
Results of the network analyses of circulating biomarkers pro-
vided independent evidence of relevant differences between the
two LV geometry groups of patients with HFrEF. In patients with
eccentric hypertrophy, NT-proBNP was the most important cen-
tral hub. This is in line with our understanding that in eccentric
hypertrophy increased wall stress is an important pathophysiolog-
ical mechanism. In our subgroup of HFrEF patients with eccentric
geometry, one of the matrix metalloproteinases (MMP2) was an
important hub. This is not surprising as matrix metalloproteinases
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Results of network analyses depicting unique protein–protein correlations in heart failure with reduced ejection fraction HFrEF with
concentric hypertrophy (A) and heart failure with reduced ejection fraction with eccentric hypertrophy (B). The size of the hub corresponds
to the betweenness centrality, which signified the importance of the hub in the network. The larger the hub, the more important it is
to the network. The edges (dotted lines) between the nodes represent the correlations with the corresponding coefficients. CASP-3,
caspase-3; EPHB4, ephrin type B receptor 4 precursor; IGFBP, insulin-like growth factor binding protein; ITGB2, integrin beta-2 precursor;
JAM-A, junctional adhesion molecule A; LDL, low-density lipoprotein; LTBR, lymphotoxin beta receptor; MMP2, matrix metalloproteinase 2;
NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAI, plasminogen activator inhibitor; PDGF, platelet-derived growth factor; PGLYRP-1,
peptidoglycan recognition protein-1; PON3, paraoxonase 3; RETN, resistin; SELP, P-selectin; TFF3, trefoil factor 3; TLT-2, TREM-like transcript
2; TNF-R1, tumour necrosis factor receptor 1; TNF-R2, tumour necrosis factor receptor 2; t-pA, tissue-type plasminogen activator; TR-AP,
tartrate-resistant acid phosphatase; U-PAR, urokinase plasminogen activator surface receptor; vWF, von Willebrand factor.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Adjusted mortality rate for patients receiving 0–49% or 50–100% of the recommended angiotensin-coverting enzyme (ACE)
inhibitor/angiotensin receptor blocker (top) or beta-blocker dose (bottom). CI, confidence interval.
are key enzymes involved in post-myocardial infarction remodelling
of the left ventricle.12 Little is known about the role of JAM-A in
heart failure. Hyperreactivity of JAM-A has been shown to accel-
erate atherosclerosis in mice.13 In contrast, in HFrEF patients with
concentric hypertrophy, U-PAR, PON3, SELP, TNF-R1 and TNF-R2
were important hubs. We will briefly discuss these proteins below.
U-PAR is a novel biomarker of chronic low-grade inflammation.
Elevated levels of U-PAR are independently associated with the inci-
dence of common co-morbidities in heart failure, such as chronic
kidney disease.14 Its soluble form has been associated with diastolic
dysfunction in HFpEF patients.15 TNF-R1 and TNF-R2 are both
cytokine receptors active in the TNF-alpha axis. The effects of this
pro-inflammatory cytokine are complex and incompletely under-
stood. In mice, overexpression of the transmembrane form of TNF .
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. leads to a phenotype of concentric hypertrophy.16 It is hypothe-
sized that the ratio between TNF-R1 and TNF-R2 is responsible
for the type of hypertrophy that develops. Interestingly, circulating
levels of TNF-R2 are known to be increased in heart failure with
preserved ejection fraction (HFpEF) relative to HFrEF in humans.17
P-selectin is a member of the selectins, a family of cell adhe-
sion molecules that are involved leucocyte migration. P-selectin
is found in platelets and endothelial cells. PON3 is a member
of the paraoxonase family, present in high-density lipoproteins,
mitochondria and the endoplasmic reticulum. Paraoxonases have
a strong anti-oxidative effect and are believed to slow the initiation
and progression of atherosclerosis. At the time of writing there
are little data on its role in heart failure.18 Overall, from our net-
work analyses we conclude that the biomarker profile of HFrEF
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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patients with concentric hypertrophy is characterized by markers
of oxidative stress and inflammation.
In addition, we explored the differential association between
LV geometry and effects of up-titration of medical therapy. Our
data suggest that for beta-blockers, the expected mortality benefit
of up-titration is higher in HFrEF patients with eccentric hyper-
trophy compared to HFrEF patients with concentric hypertrophy.
However, these results might be influenced by the relatively low
number of patients with concentric hypertrophy. For ACEi/ARBs,
we could not establish a statistically significant interaction between
LV geometry and the effect of up-titration on mortality. Nonethe-
less, the point estimates of hazard ratio are lower in successfully
up-titrated patients in eccentric hypertrophy compared to concen-
tric hypertrophy. These observations are in line with an analysis
of the Valsartan Heart Failure Trial (Val-HeFT) echocardiographic
data showing that patients with the largest LV internal diastolic
diameters had the greatest relative and absolute risk reduction
in response to valsartan.19 These findings cannot be explained by
the assumption that patients with eccentric hypertrophy are more
severe patients with a higher risk, since the Kaplan–Meier curves
for the non-up-titrated patients showed similarly dismal progno-
sis in eccentric hypertrophy (Figure 4). We therefore hypothesize
that, in addition to ejection fraction, geometry of the left ventricle
might influence the response to up-titration of beta-blockers and
ACEi/ARBs.
Unfortunately, our study has some limitations. First, the number
of patients in the concentric hypertrophy group was smaller than
in the eccentric group. Furthermore, the assessment of echocar-
diography was not performed in an echo core lab. Moreover,
this is a post-hoc analysis of a prospective study, introducing the
risk of residual confounding. However, every effort was made to
account for known potential confounders and results were con-
sistent in both index and validation cohorts. Next, we studied
protein–protein interactions using correlations only. Other meth-
ods of analysis, for instance incorporating existing knowledge on
physical interactions in the networks, might offer additional infor-
mation. Although we did not include patients with HFpEF in this
analysis, a future question of particular interest would be whether a
subset of HFpEF patients with eccentric hypertrophy would benefit
from ACEi and beta-blockers. Finally, since the majority of patients
in this study are of Caucasian origin, it is not known if results are
generalizable to other populations.
Conclusion
Patients with HFrEF with concentric LV hypertrophy have a clin-
ical and biomarker phenotype that is different from HFrEF with
eccentric LV hypertrophy. Patients with HFrEF and concentric LV
hypertrophy may not experience similar benefit from up-titration
of ACEi/ARBs and beta-blockers compared to HFrEF with eccen-
tric LV hypertrophy.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article. ..
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.. Table S1. Baseline characteristics of the validation cohort.
Table S2. Measurements using Olink Proseek®.
Table S3. Baseline characteristics of the index cohort, including
patients with normal geometry and concentric remodelling
Figure S1. Overall survival in the index cohort stratified by left
ventricular geometry.
Figure S2. Overall survival in the validation cohort stratified by
left ventricular geometry.
Figure S3. Unweighted Kaplan–Meier curves for <50% up-
titration vs. >50% up-titration of angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers and beta-blockers.
Figure S4.Heatmap of protein–protein correlations in concentric
hypertrophy.
Figure S5. Heatmap of protein–protein correlations in eccentric
hypertrophy.
Figure S6. Flow-chart of patient selection.
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